213 related articles for article (PubMed ID: 11602813)
41. Hemodynamic effects of esmolol in chronically beta-blocked patients undergoing aortocoronary bypass surgery.
de Bruijn NP; Croughwell N; Reves JG
Anesth Analg; 1987 Feb; 66(2):137-41. PubMed ID: 2880530
[TBL] [Abstract][Full Text] [Related]
42. Effects of esmolol on patients with left ventricular dysfunction.
Iskandrian AS; Bemis CE; Hakki AH; Panidis I; Heo J; Toole JG; Hua TA; Allin D; Kane-Marsch S
J Am Coll Cardiol; 1986 Jul; 8(1):225-31. PubMed ID: 2872244
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of near infrared spectroscopy for detecting the β blocker-induced decrease in cerebral oxygenation during hemodilution in a swine model.
Kurita T; Morita K; Sato S
J Clin Monit Comput; 2015 Dec; 29(6):779-88. PubMed ID: 25876017
[TBL] [Abstract][Full Text] [Related]
44. Esmolol, the first ultra-short-acting intravenous beta blocker for use in critically ill patients.
Blanski L; Lutz J; Laddu A
Heart Lung; 1988 Jan; 17(1):80-9. PubMed ID: 3276651
[TBL] [Abstract][Full Text] [Related]
45. High-Dose Glucagon Has Hemodynamic Effects Regardless of Cardiac Beta-Adrenoceptor Blockade: A Randomized Clinical Trial.
Petersen KM; Bøgevig S; Riis T; Andersson NW; Dalhoff KP; Holst JJ; Knop FK; Faber J; Petersen TS; Christensen MB
J Am Heart Assoc; 2020 Nov; 9(21):e016828. PubMed ID: 33103603
[TBL] [Abstract][Full Text] [Related]
46. Electrophysiologic, cardiohemodynamic and beta-blocking actions of a new ultra-short-acting beta-blocker, ONO-1101, assessed by the in vivo canine model in comparison with esmolol.
Sugiyama A; Takahara A; Hashimoto K
J Cardiovasc Pharmacol; 1999 Jul; 34(1):70-7. PubMed ID: 10413070
[TBL] [Abstract][Full Text] [Related]
47. A rest and exercise haemodynamic evaluation of a new cardio-selective beta-adrenoceptor blocker celiprolol alone and in combination with nitroglycerine in ischaemic heart disease.
Silke B; Verma SP; Frais MA; Reynolds G; Taylor SH
Br J Clin Pharmacol; 1986 Dec; 22(6):697-706. PubMed ID: 2882772
[TBL] [Abstract][Full Text] [Related]
48. Ultra-short-acting beta-blockade: a comparison with conventional beta-blockade.
Reilly CS; Wood M; Koshakji RP; Wood AJ
Clin Pharmacol Ther; 1985 Nov; 38(5):579-85. PubMed ID: 2865029
[TBL] [Abstract][Full Text] [Related]
49. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
[TBL] [Abstract][Full Text] [Related]
50. Comparison of the acute hemodynamic effects of intravenous celiprolol and propranolol in patients with suspected coronary disease.
Gensini G; Dator C; Esente P; Caruso FS; Solomon T
J Cardiovasc Pharmacol; 1986; 8 Suppl 4():S83-5. PubMed ID: 2427857
[TBL] [Abstract][Full Text] [Related]
51. Hemodynamic and metabolic effects of selective beta1 adrenergic blockade during sepsis.
Gore DC; Wolfe RR
Surgery; 2006 May; 139(5):686-94. PubMed ID: 16701103
[TBL] [Abstract][Full Text] [Related]
52. Defining the dose range for esmolol used in electroconvulsive therapy hemodynamic attenuation.
Howie MB; Hiestand DC; Zvara DA; Kim PY; McSweeney TD; Coffman JA
Anesth Analg; 1992 Nov; 75(5):805-10. PubMed ID: 1358003
[TBL] [Abstract][Full Text] [Related]
53. Interactions of esmolol and adenosine in atrioventricular nodal-dependent supraventricular tachycardia: implication for the cellular mechanisms of adenosine.
Chang KC; Lin YC; Chen JY; Chou HT; Hung JS
Cardiology; 2002; 97(3):138-46. PubMed ID: 12077566
[TBL] [Abstract][Full Text] [Related]
54. Microvascular effects of intravenous esmolol in patients with normal cardiac function undergoing postoperative atrial fibrillation: a prospective pilot study in cardiothoracic surgery.
Fornier W; Jacquet-Lagrèze M; Collenot T; Teixeira P; Portran P; Schweizer R; Ovize M; Fellahi JL
Crit Care; 2017 Dec; 21(1):302. PubMed ID: 29233190
[TBL] [Abstract][Full Text] [Related]
55. Managing critically ill patients with esmolol. An ultra short-acting beta-adrenergic blocker.
Gray RJ
Chest; 1988 Feb; 93(2):398-403. PubMed ID: 2892647
[TBL] [Abstract][Full Text] [Related]
56. [Acute changes of coronary and global hemodynamics in patients with angina pectoris and arterial hypertension caused by celiprolol and metoprolol].
Franz N; Modersohn D; Linss G; Heublein B; Gola G; Bruch L; Walde T
Radiol Diagn (Berl); 1990; 31(6):625-8. PubMed ID: 1982742
[TBL] [Abstract][Full Text] [Related]
57. Esmolol and beta-adrenergic blockade.
Wolman RL; Fiedler MA
AANA J; 1991 Dec; 59(6):541-8. PubMed ID: 1686346
[TBL] [Abstract][Full Text] [Related]
58. Beta-receptor antagonism does not fully explain esmolol-induced hypotension.
Deegan R; Wood AJ
Clin Pharmacol Ther; 1994 Aug; 56(2):223-8. PubMed ID: 7914845
[TBL] [Abstract][Full Text] [Related]
59. The effect of single bolus dose of esmolol for controlling the tachycardia and hypertension during laryngoscopy and tracheal intubation.
Yuan L; Chia YY; Jan KT; Chen CS; Wang CH; Haung LH; Kang L
Acta Anaesthesiol Sin; 1994 Sep; 32(3):147-52. PubMed ID: 7921858
[TBL] [Abstract][Full Text] [Related]
60. Maternally administered esmolol produces fetal beta-adrenergic blockade and hypoxemia in sheep.
Eisenach JC; Castro MI
Anesthesiology; 1989 Nov; 71(5):718-22. PubMed ID: 2573294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
